These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33470162)

  • 21. Meta-Analysis of Capecitabine versus 5-Fluorouracil in Advanced Gastric Cancer.
    Wu Z; Zhang X; Zhang C; Lin Y
    Evid Based Complement Alternat Med; 2023; 2023():4946642. PubMed ID: 37408581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer].
    Lu CX; Zheng BW; Bai B; Hu JL; Fan SF; Shang DF; Yang D; Zhao CL; Cang SD
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):708-711. PubMed ID: 31550863
    [No Abstract]   [Full Text] [Related]  

  • 23. A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
    LoConte NK; Holen KD; Schelman WR; Mulkerin DL; Deming DA; Hernan HR; Traynor AM; Goggins T; Groteluschen D; Oettel K; Robinson E; Lubner SJ
    Invest New Drugs; 2013 Aug; 31(4):943-8. PubMed ID: 23263993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of patients' knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat.
    Nouibi C; Cherif Chefchaouni A; Bechar H; Belahcen MJ; Rahali Y
    J Oncol Pharm Pract; 2023 Oct; 29(7):1708-1714. PubMed ID: 36637236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and severity of hand-foot syndrome in cancer patients receiving infusional 5-fluorouracil or oral capecitabine-containing chemotherapy regimens.
    Abdul Kareem S; Joseph SG; Wilson A; Kareem SA; Kunjumon Vilapurathu J
    J Oncol Pharm Pract; 2024 Jan; ():10781552241228175. PubMed ID: 38263642
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer.
    Chan SL; Chan AWH; Mo F; Ma BBY; Wong KCW; Lam D; Mok FST; Chan ATC; Mok T; Chan KCA
    Oncologist; 2018 Dec; 23(12):1436-1445. PubMed ID: 29802221
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
    Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine.
    Walter T; Wang L; Chuk K; Ng P; Tannock IF; Krzyzanowska MK
    J Oncol Pharm Pract; 2014 Aug; 20(4):249-56. PubMed ID: 24022406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of oral administration of cystine and theanine in patients with colorectal cancer undergoing capecitabine-based adjuvant chemotherapy after surgery: study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled, phase II trial.
    Hamaguchi R; Tsuchiya T; Miyata G; Sato T; Takahashi K; Ariyoshi K; Oyamada S; Iwase S
    BMJ Open; 2018 Jul; 8(7):e021442. PubMed ID: 30030317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics.
    Jackson K; Letton C; Maldonado A; Bodiford A; Sion A; Hartwell R; Graham A; Bondarenka C; Uber L
    J Oncol Pharm Pract; 2019 Jun; 25(4):847-854. PubMed ID: 29587608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices.
    Salgado TM; Mackler E; Severson JA; Lindsay J; Batra P; Petersen L; Farris KB
    Support Care Cancer; 2017 Jun; 25(6):1797-1807. PubMed ID: 28108821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.
    Blum JL; Jones SE; Buzdar AU; LoRusso PM; Kuter I; Vogel C; Osterwalder B; Burger HU; Brown CS; Griffin T
    J Clin Oncol; 1999 Feb; 17(2):485-93. PubMed ID: 10080589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.
    Díaz-Rubio E; Evans TR; Tabemero J; Cassidy J; Sastre J; Eatock M; Bisset D; Regueiro P; Baselga J
    Ann Oncol; 2002 Apr; 13(4):558-65. PubMed ID: 12056706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
    Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
    Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Oral Chemotherapy Management Program on Capecitabine Toxicity Management.
    Nhean S; Kostoff D; Yang JJ; Vogel V; Rybkin II
    JCO Oncol Pract; 2021 Jul; 17(7):e1021-e1029. PubMed ID: 33900803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
    Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
    Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice.
    Timmers L; Boons CC; Mangnus D; Van de Ven PM; Van den Berg PH; Beeker A; Swart EL; Honeywell RJ; Peters GJ; Boven E; Hugtenburg JG
    Front Pharmacol; 2016; 7():310. PubMed ID: 27708578
    [No Abstract]   [Full Text] [Related]  

  • 40. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer.
    Li YH; Luo HY; Wang FH; Wang ZQ; Qiu MZ; Shi YX; Xiang XJ; Chen XQ; He YJ; Xu RH
    J Cancer Res Clin Oncol; 2010 Apr; 136(4):503-10. PubMed ID: 19777259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.